	US 12,186,286 B2
	Use of senicapoc for treatment of stroke
Roland Staal, Metuchen, NJ (US); Jonathan Weinstein, Seattle, WA (US); and Thomas Moeller, Brookline, MA (US)
Assigned to Paracelsus Neuroscience LLC, Metuchen, NJ (US)
Filed by Paracelsus Neuroscience II, LLC, Metuchen, NJ (US)
Filed on Jul. 18, 2022, as Appl. No. 17/813,158.
Application 17/813,158 is a continuation of application No. 16/481,779, filed on Jul. 29, 2019, granted, now 11,395,807.
Prior Publication US 2023/0045322 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/165 (2006.01); A61K 9/00 (2006.01); A61P 9/10 (2006.01)

CPC A61K 31/165 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61P 9/10 (2018.01)]

3 Claims

1. A method of treating ischemia/reperfusion brain injury, comprising the inhibition of calcium activated potassium channel K_Ca3.1 on microglia in the brain, by administering to a patient experiencing ischemia/reperfusion brain injury an amount of senicapoc sufficient to inhibit the calcium activated potassium channel K_Ca3.1 in brain microglia where the inhibition of microglia is sufficient to achieve a 50% inhibition in the release of nitric oxide from microglia in the brain when the senicapoc is administered to a patient.